Phase 1b trial findings indicate that telisotuzumab vedotin, given in combination with erlotinib, may have potential as a treatment option for progressing EGFR mutation-positive non-small-cell lung cancer with c-Met overexpression.

The addition of bevacizumab to erlotinib does not improve the overall survival of treatment-naïve patients with advanced non-small-cell lung cancer harboring an activating EGFR mutation, NEJ026 study data show.

Combining erlotinib with bevacizumab is associated with a significant prolongation of progression-free survival in chemotherapy-naïve patients with advanced nonsquamous non-small-cell lung cancer harboring an activating EGFR mutation, indicates a phase III trial.

A phase 2 trial suggests that low-dose erlotinib has clinical activity and a favorable safety profile among older and frail non-small-cell lung cancer patients with EGFR activating mutations.

medwireNews : The EMA has adopted a positive opinion  recommending use of the VEGFR2 inhibitor ramucirumab as a first-line treatment for metastatic non-small-cell lung cancer (NSCLC) alongside the EGFR inhibitor erlotinib.

Adding bevacizumab to erlotinib does not improve the outcomes of previously untreated patients with EGFR mutation-positive advanced non-small-cell lung cancer, finds a phase II trial.

Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

Adjuvant erlotinib significantly prolongs disease-free survival, compared with a historic benchmark, in patients with epidermal growth factor receptor - mutated stage IA–IIIA non-small-cell lung cancer, US research shows.

After surgery, the patients continued their treatment as per the random assignment, with the only difference being that adjuvant erlotinib was given for 12 months.

The team adds that this makes “it a promising clinical candidate both as a single agent and in combination with other anticancer therapies,” and divarasib is being evaluated alongside agents such as atezolizumab, bevacizumab, and erlotinib in this current, ongoing study.

The analysis included data on 168 patients (89 with NSCLC, 79 with melanoma) who received first-line TKI therapy with dabrafenib, vemurafenib, gefitinib, afatinib, or erlotinib between January 2015 and April 2017 at The Christie NHS Foundation Trust.

Specifically, median PFS was longest with afatinib, at 12.0 months, and shortest with erlotinib, at 3.8 months.

The current analysis – published as a research letter in JAMA Oncology – included 133 diabetes-free participants of a Mexican phase 2 study that investigated the addition of metformin 500 mg twice a day to an EGFR–TKI (erlotinib, afatinib, or gefitinib) for the treatment of stage IIIB–IV NSCLC with an activating EGFR mutation.

The FLAURA trial comparing osimertinib with erlotinib or gefitinib in the first-line treatment of EGFR -mutated, advanced non-small-cell lung cancer has shown positive overall survival results favoring the third-generation EGFR–tyrosine kinase inhibitor.

FLAURA is a phase III trial pitting the third-generation EGFR–tyrosine kinase inhibitor osimertinib against gefitinib or erlotinib for the first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer.

The FoundationOne Liquid CDx (Foundation Medicine Inc, Cambridge, Massachusetts, USA) has been approved as a companion diagnostic test for identification of EGFR exon 19 deletions and exon 21 L858R alterations for use of gefitinib, osimertinib, and erlotinib in patients with non-small-cell lung cancer.

Suresh Ramalingam presents the overall survival analysis of the FLAURA trial of osimertinib in EGFR mutation-positive, advanced non-small-cell lung cancer, and discusses the options after progression on the tyrosine kinase inhibitor (1:50).

Their phase I trial enrolled individuals who had developed resistance to erlotinib, gefitinib, or afatinib – but were negative for the EGFR T790M mutation – or had progressed on osimertinib.

Sammons Cancer Center, Dallas) and co-workers say data from the US Oncology Network iKnowMed TM electric health records for 2015–2017 show that 98% of 308 EGFR -positive patients received EGFR–TKI therapy, most commonly the first-generation agent erlotinib, but just 26% subsequently received a second-line treatment.